Table 4.
Univariate analysis of possible risk factors for hepatic decompensation in primary biliary cirrhosis
| Decompensation free (n = 196) | Decompensation (n = 62) | P value | |
| Age at diagnosis (yr) | 50.2 | 55.6 | < 0.001 |
| Gender (female/male) | 178/18 | 59/3 | 0.275 |
| Symptoms | 60.20% | 80.65% | 0.003 |
| UDCA treatment | 85.20% | 30.65% | < 0.001 |
| ANA | 64.80% | 80.65% | 0.019 |
| AMA | 92.86% | 95.16% | 0.731 |
| ACA | 19.39% | 56.45% | < 0.001 |
| ALT (IU/L) | 89.6 | 96.6 | 0.109 |
| AST (IU/L) | 80.6 | 103.2 | < 0.001 |
| AST/ALT | 1.05 | 1.27 | 0.013 |
| ALP (IU/L) | 311.6 | 454.1 | < 0.001 |
| GGT (IU/L) | 395.4 | 524.3 | 0.001 |
| ALB (g/L) | 41.5 | 38.4 | < 0.001 |
| TBil (μmol/L) | 20.92 | 48.84 | < 0.001 |
| DBil (μmol/L) | 9.27 | 29.06 | < 0.001 |
| IgG (g/L) | 16.61 | 17.43 | 0.386 |
| IgA (g/L) | 2.99 | 3.62 | 0.004 |
| IgM (g/L) | 4.61 | 4.83 | 0.285 |
| Histological stage1 (I-II) | 92.22% | 66.67% | 0.008 |
| Early PBC | 9.70% | 0.00% | 0.023 |
| Extra-hepatic autoimmune disease | 37.24% | 37.10% | 0.983 |
1
n = 108. ANA: Anti-nuclear antibody; AMA: Anti-mitochondrial antibody; ACA: Anti-centromere antibody; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: γ-glutamyl-transferase; ALB: Albumin; TBil: Total bilirubin; DBil: Direct bilirubin; UDCA: Ursodeoxycholic acid; Ig: Immunoglobulin.